Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome

Psychological Morbidity and Facial Volume in HIV Lipodystrophy:

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01359917

Enrollment

Registered

2011-05-25

Start date

2006-08-31

Completion date

2009-07-31

Last updated

2011-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-Associated Lipodystrophy Syndrome

Brief summary

The hypotheses of this study were that: 1. HIV lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression. 2. Treatment of HIV lipodystrophy using autologous fat transfer, polylactic acid or Bio-alcamid, is associated with an improvement in psychological morbidity and anatomical volume of treated areas. 3. The DI3D system is a valid and reproducible method of recording and measuring facial 3-D volume.

Detailed description

as above

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* HIV facial lipoatrophy * concurrent antiretrovirals

Exclusion criteria

* known psychological disorder * skin allergies * significant medical problems precluding anaesthesia

Design outcomes

Primary

Measure	Time frame	Description
measurement of 3-D facial volume	2 years	3-D facial camera

Secondary

Measure	Time frame	Description
psychological outcome	2 years	derriford appearance scale hospital anxiety and depression scale

Outcome results